The Asia-Pacific High Potency Active Pharmaceutical Ingredients Market was worth USD 3.5 billion in 2016 and estimated to be growing at a CAGR of 9.1%, to reach USD 5.4 billion by 2021.
- Advertising -
High Potency Active Pharmaceutical Ingredients (HPAPI) are a group of pharmacological substances and intermediates, active at concentrations of 150 micrograms per kilogram of body weight or below. They are characterised by high specificity, so they can bind to specific receptors or to specific enzymes which can cause cancer, reproductive problems and developmental disorders at low doses.
The growth of this market is high as many new drugs have these HPAPI’s.
View Full Report at marketdataforecast.com/market-repo…ents-market-3027/
High Potency Active Pharmaceutical Ingredients gave rise to alternative methods of treatment by different drugs, notably cancer.
- Advertising -
After the human genome mapping, new drugs for cancer could be made not only for different cancers but also for different patients. Their production is to be done with great care since they are active even at low concentrations.
They can pose grave consequences to workers if proper care is not taken during production. Special care has to be taken to prevent contamination of drugs with contaminants.
So it requires specialized equipment for handling HPAPI’s and managing air quality.
The Asia-Pacific High Potency Active Pharmaceutical Ingredients market has driving factors such as low price, growing government initiatives to increase the usage of generic medicines to cut down healthcare costs, growing healthcare prices, rising number of pharmaceutical manufacturers and patients. However the market is constrained by factors like lack of skilled workers, stringent regulatory requirements and high price of equipment.
The Asia-Pacific High Potency Active Pharmaceutical Ingredients market is segmented on the basis of type into innovative HPAPI’s and generic HPAPI’s. Innovative HPAPI’s has the largest market share due to factors like many number of them being patented, higher price as compared to generics, pharmaceutical manufacturers focusing on production of new drugs and demand for novel anti-cancer medicines.
Based on synthesis, the market is divided into biotech HPAPI’s and synthetic HPAPI’s. Synthetic HPAPI’s have a larger market share due to rise of new drugs in the market, ease of production, technological improvements in synthesis and approval for the production of new drugs.
Based on therapeutic application, the market is segmented into oncology, glaucoma, hormonal balance and others. Oncology has the largest share in the market.
Factors such as rising incidence of cancer and launch of new target therapies is the reason for rise in the therapeutic segment.
The Asia-Pacific High Potency Active Pharmaceutical Ingredients market is geographically segmented into India, China, Australia, Thailand and other countries of Asia-Pacific. This region is expected to be the fastest growing region in the world.
Factors such as increased funding into cancer research, rising number of people diagnosed with cancer and approval for the production of new drugs is going to boost the growth of this market in the region.
Some of the major players in the market include Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), F.
Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), Bristol-Myers Squibb (U.S.), Boehringer Ingelheim (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc.
(U.S.), AbbVie Inc. (U.S.), and Mylan Inc. (U.S.).
Category: Market Research Publishers and RetailersCompany profile: Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients. A few key business areas that we handle with excellence include business process improvement, corporate financing and decision making based on market research, assisting in developing appropriate strategy and providing consultancy based on extens ...
For more information: